In a nutshell This study examined the link between circulating tumor cells (CTCs) and treatment outcome in metastatic castration-resistant prostate cancer (mCRPC). Authors reported better survival outcomes for mCRPC patients with a significant decline in CTC count during treatment. Some background Metastatic castration-resistant prostate...
Read More
In a nutshell This study analyzed predictors of treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that testosterone levels before treatment can help predict overall survival in men with mCRPC. Some background Hormone therapy is the standard of care for advanced prostate cancer, including...
Read MoreIn a nutshell This phase 2 trial aims to evaluate combinations of hormone therapies, a steroid drug, an immunotherapy drug, and chemotherapy in the treatment of metastatic castration-resistant prostate cancer. The main outcome to be investigated is overall survival (time from treatment until death from any cause). The trial is recruiting in Houston,...
Read More
In a nutshell This study investigated the effects of health status in older patients with metastatic castration-resistant prostate cancer on treatment outcome with taxane-based chemotherapies. Researchers reported that taxane-based chemotherapies were associated with a significant survival benefit, regardless of age and health status. Some background...
Read More
In a nutshell The authors aimed to determine outcomes in patients with whose prostate cancer has spread to the lymph nodes and were treated with prostate surgery but without accompanying hormone treatment. Some background In some patients prostate cancer tumors can spread to other parts of the body, including the lymph nodes which hold the...
Read More
In a nutshell The present study evaluated the efficacy of dutasteride (Avodart) in delaying PSA progression in patients who experienced recurrence after radical therapy for prostate cancer (PCa). PCa progression was significantly reduced in patients who received treatment with dutasteride. Some background Most patients with PCa receive treatment...
Read More
In a nutshell This article reports the results of recent studies involving the drug Docetaxel (Taxotere). The drug did not improve overall survival when added to androgen-deprivation therapy. Smaller doses given in shorter treatment cycles were found to be easier to tolerate and more effective. Some background Prostate cancer grows in...
Read More
The present clinical trial evaluated the safety of an immune-based therapy (termed ‘combined immunotherapy’) as an alternative to chemotherapy for the treatment of metastatic (spread with distant metastases) prostate cancer non-responsive to hormonal treatment, or ‘castration-resistant prostate cancer’ (mCRPC). The trial aimed...
Read More
